For your patients who have von Willebrand disease (VWD)

Bleeding control when
they need it most

#1 Prescribed VWF replacement therapy 1
#1 Prescribed VWF replacement therapy 1

HUMATE-P provides bleed control across all VWD types, including Type 3—the most severe

“Excellent” or “Good” overall clinical response demonstrated across the majority of treatment events in a retrospective study (N=97)*2

Treatment Events

424/437

treatment events

Nonsurgical bleeds rate

332/344 nonsurgical

bleeding events

Surgical intervention rate

72/73 surgeries

*Retrospective review of 97 Canadian patients. Excellent was defined as hemostasis achieved/complete cessation of bleeding.
Good was defined as slight oozing/partial but adequate control of bleeding and did not require additional product for unplanned treatment.2

*Retrospective review of 97 Canadian patients. Excellent was defined as hemostasis achieved/complete cessation of bleeding. Good was defined as slight oozing/partial but adequate control of bleeding and did not require additional product for unplanned treatment.2

Bekah’s birthing experience with HUMATE-P

quote

I’m very glad that I made the choice to use HUMATE-P. It worked very well for me." —Bekah, HUMATE-P user

Individual patient experiences may vary.

Bekah’s birthing experience with HUMATE-P

quote

I’m very glad that I made the choice to use HUMATE-P. It worked very well for me."

—Bekah, HUMATE-P user

Individual patient experiences may vary.

Baby in blanket
Icon of bandage

VWF + FVIII for

effective bleed control

Icon of shield

30+ years of safe,

effective bleed control

Icon of vial

Tools to help simplify

VWF dosing

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

CSL Behring provides additional treatment options to support the bleeding disorder community:

Learn about a treatment that makes zero bleeds a possibility for your hemophilia B patients

Visit the Product Website

Explore a twice-weekly dosing option for your hemophilia A patients

Visit the Product Website
References
  1. Data on file. Available from CSL Behring as DOF HUM-002.
  2. Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/ HUMATE-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87(2):224-230.

You are now leaving the current website.

Do you want to continue?

Yes No